Skip to main content

Table 4 Acute toxicities in the 394 NPC patients

From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Acute toxicity

NTZ group

N = 50 (%)

Non-NTZ group

N = 344 (%)

P value

Leukopenia

0.739

 G0–G1

18 (36.00)

129 (37.50)

 

 G2

14 (28.00)

100 (29.07)

 

 G3

14 (28.00)

91 (26.45)

 

 G4

4 (8.00)

24 (6.98)

 

Neutropenia

0.947

 G0–G1

26 (52.00)

173 (50.29)

 

 G2

13 (26.00)

98 (28.49)

 

 G3

10 (20.00)

73 (21.22)

 

 G4

1 (2.00)

0

 

Anemia

0.811

 G0–G1

40 (80.00)

279 (81.10)

 

 G2

7 (14.00)

51 (14.83)

 

 G3

3 (6.00)

14 (4.07)

 

Thrombocytopenia

0.650

 G0–G1

45 (90.00)

316 (91.86)

 

 G2

4 (8.00)

24 (6.98)

 

 G3

1 (2.00)

4 (1.17)

 

Hepatotoxicity

0.760

 G0–G1

43 (86.00)

290 (84.30)

 

 G2

5 (10.00)

39 (11.34)

 

 G3

2 (4.00)

15 (4.36)

 

Nephrotoxicity

0.671

 G0–G1

47 (94.00)

318 (92.44)

 

G2

3 (6.00)

19 (5.52)

 

 G3

0

7 (2.03)

 

Skin reaction

0.866

 G0–G1

37 (74.00)

257 (74.71)

 

 G2

11 (22.00)

79 (22.97)

 

 G3

2 (4.00)

8 (2.33)

 

Mucositis

0.594

 G0–G1

16 (32.00)

117 (34.01)

 

 G2

19 (38.00)

139 (40.41)

 

 G3

13 (26.00)

76 (22.09)

 

 G4

2 (4.00)

12 (3.49)

 

Nausea

0.895

 G0–G1

27 (54.00)

178 (51.74)

 

 G2

17 (34.00)

130 (37.79)

 

 G3

4 (8.00)

31 (9.01)

 

 G4

2 (4.00)

5 (1.45)

 

Vomiting

0.803

 G0–G1

35 (70.00)

233 (67.73)

 

 G2

9 (18.00)

72 (20.93)

 

 G3

6 (12.00)

39 (11.34)

 

Diarrhea

0.693

 G0–G1

44 (88.00)

309 (89.83)

 

 G2

6 (12.00)

35 (10.17)

 

Weight loss

0.623

 G0–G1

38 (76.00)

271 (78.78)

 

 G2

10 (20.00)

65 (18.90)

 

 G3

2 (4.00)

8 (2.33)